Recently the guideline ‘Treatment multiple myeloma 2018’ was published. Below are the most important changes from the 2015 guideline. These changes concern the initial treatment of patients eligible for autologous stem cell transplantation, the initial treatment of patients who are not eligible for autologous stem cell transplantation and the patients with a relapse of the sickness. The changes are based on new clinical data that have become available from randomized phase 3 trials. The most recent version of the entire guideline can be found on the websites of both the NVvH and HOVON. The guideline will be adjusted per module. The expectation is that this will already happen in the coming months as several treatment combinations will be registered and hopefully also be available in the short term. This summary concerns patients who cannot be treated in a trial context. At all times treatment within a study context is preferable
